Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, GlaxoSmithKline rose $0.64 (1.2%) to $53.00 on light volume. Throughout the day, 1,474,734 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2,434,300 shares. The stock ranged in a price between $52.72-$53.21 after having opened the day at $53.19 as compared to the previous trading day's close of $52.36. Other companies within the Drugs industry that increased today were:




), up 16.0%,

Merus Labs International



), up 14.6%,

Cardium Therapeutics



TheStreet Recommends

), up 13.9% and

CytRx Corporation



), up 13.8%.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $126.2 billion and is part of the health care sector. Shares are up 20.4% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Mast Therapeutics



), down 39.8%,

Coronado Biosciences



), down 9.5%,

Tekmira Pharmaceuticals Corporation



), down 6.8% and

Hyperion Therapeutics



), down 6.4% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.